Also trades as: ESLA (NASDAQ) · $vol 0M
ESLAW NASDAQ
Estrella Immunopharma, Inc.
1W: -1.0%
1M: -51.4%
3M: -11.7%
YTD: -26.4%
1Y: -4.1%
$0.07
+0.01 (+10.33%)
Weekly Expected Move ±44.8%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$13M
-47.7% ▼
Net Income
-$13M
-47.6% ▼
EPS (Diluted)
$-0.35
-40.0% ▼
EBITDA
-$13M
-47.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $1M | $0 | $4M | $6M | $10M |
| SG&A Expenses | $296K | $1M | $3M | $2M | $3M |
| Operating Expenses | $2M | $2M | $7M | $9M | $13M |
| Operating Income | -$2M | -$2M | -$7M | -$9M | -$13M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$2M | -$915K | -$7M | -$9M | -$13M |
| Tax Expense | -$235K | $81K | $2K | $2K | $838 |
| Net Income | -$2M | -$996K | -$7M | -$9M | -$13M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-0.29 | $-0.17 | $-0.21 | $-0.25 | $-0.35 |
| EBITDA | -$11K | -$687K | -$7M | -$9M | -$13M |
| Shares Outstanding | 6M | 6M | 35M | 37M | 37M |